Gilead Sciences completes acquisition of YM BioSciences
Gilead Sciences, Inc. today announced that it has completed its acquisition of YM BioSciences Inc..
Gilead Sciences Inc. has agreed to buy YM BioSciences Inc. for $510 million in cash, as the drug company looks to boost its oncology portfolio.